Kidney Transplant Recipient Response to Shingrix Vaccine study: Shingrix
Official title Shingrix in Renal Transplant Recipients
ClinicalTrials.gov ID: NCT04128189
What this study is testing
What is Shingrix?
An investigational vaccine being studied to protect kidney transplant recipients from shingles.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see how well the shingles vaccine works and how safe it is in people with kidney failure who are waiting for or receive a kidney transplant. It also tests whether a third dose after transplant improves protection.
- Who it's for
- Adults with kidney failure who are waiting for a kidney transplant, and those who receive a transplant during the study.
- What's involved
- Participants will have up to 6 visits over 30‑37 months. They will receive two doses of Shingrix if not already vaccinated, or have assessments if already vaccinated. If they get a transplant, they may be randomly given a third dose or none. They will fill out questionnaires, have physical exams, and give blood (and urine) samples at visits.
- Time commitment
- The study lasts about 30‑37 months and involves 3 to 6 study visits, including follow‑up after a transplant if it occurs.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Adults with chronic kidney failure who are listed for kidney transplantation at participating transplant centers.
- Age 18 to 70 years Able and willing to provide written informed consent Currently on the waiting list for kidney transplantation at a participating...
- Eligible to receive Shingrix at study entry per CDC-recommended schedule, or Previously completed the Shingrix vaccination series within 3 to 24...
- Use adequate contraception for at least 30 days prior to vaccination Have a negative pregnancy test on the day of each vaccination Agree to continue...
You likely can't join if
- Active immunosuppressive or immunodeficient condition (e.g., malignancy, HIV infection) or receipt of immunosuppressive therapy within 3 months prior...
The study team makes the final eligibility decision.
Where it is enrolling
- Aurora, Colorado, United States
- Atlanta, Georgia, United States
- Boston, Massachusetts, United States
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Aurora, Colorado, United States; Atlanta, Georgia, United States; Boston, Massachusetts, United States; Houston, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.